Volta

Protective immunity against tuberculosis in a free‐living badger population vaccinated orally with Mycobacterium bovis Bacille Calmette–Guérin

Unknown authors · 2021
hash_id: 87cce93a8b500b5616f948e8884e3661cb4d81acbac8c3dbf208b713509da8df · DOI: 10.1111/tbed.14254

Vaccination of badgers with Mycobacterium bovis Bacille Calmette-Guérin (BCG) has been shown to protect badgers against tuberculosis in experimental trials. During the 3-year County Kilkenny BCG vaccine field study, badgers were treated orally with placebo (100% in Zone A), BCG (100% in Zone C) or randomly assigned 50%: 50% treatment with BCG or placebo (Zone B). At the end of the study, 275 badgers were removed from the trial area and subjected to detailed post-mortem examination followed by histology and culture for M. bovis. Among these badgers, 83 (30.2%) were captured for the first time across the three zones, representing a non-treated proportion of the population. Analysis of the data based on the infection status of treated animals showed a …

Reference & gravity metrics

Citations
0
Citations / yr
0.00
RCR
Mass
0.00
Depth
0.00
Momentum
0.000
Burn rate
0.00 ATP/day
Start price
25.00 ATP

Secondary-market trade history

No secondary-market trades recorded for this Volta yet.

References (0)

No outbound references recorded.

Cited by (2)

Mycobacterium bovis Infection in the Eurasian Badger (Meles meles): the Disease… secondary
The distribution of Mycobacterium bovis infection in naturally infected badgers secondary